Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical Study of MiR-125b-5p/HIF-1α Pathway in Involvement of Vitamin D Deficiency in Pathogenesis of Multiple Myeloma].

Zhongguo shi yan xue ye xue za zhi·2026
Same author

[Construction and Evaluation of Risk Prediction Model of Delayed Excretion in Adult Acute Lymphoblastic Leukemia Patients Treated with High-Dose Methotrexate].

Zhongguo shi yan xue ye xue za zhi·2025
Same author

[Clinical Study on Dynamic Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multiparameter Flow Cytometry].

Zhongguo shi yan xue ye xue za zhi·2022
Same author

Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2022
Same author

[Clinical Research of Dendritic Cell-Mediated Tumor-Associated Antigen-Specific Cytotoxic T Lymphocytes in the Treatment of Multiple Myeloma and Non-Hodgkin Lymphoma].

Zhongguo shi yan xue ye xue za zhi·2020
Same author

[Effect of Chidamide on the Killing Acitivity of NK Cells Targeting K562 Cells and Its Related Mechanism In Vitro].

Zhongguo shi yan xue ye xue za zhi·2020
Same journal

[Research Progress on the Bone Marrow Microenvironment in Beta-Thalassemia --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of CAR-T Cell Therapy in Autoimmune Diseases --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress in Venetoclax-Based Combination Therapy in Acute Myeloid Leukaemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Advances in the Treatment of Acute Myeloid Leukemia with <i>TP53</i> Mutations-Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Analysis of Risk Factors and Clinical Characteristics of Early Death in Patients with Hemophagocytic Syndrome].

Zhongguo shi yan xue ye xue za zhi·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

[CD47 and leukemia stem cells].

Qian-Song Cheng1, Xing-Bing Wang

  • 1Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, Anhui Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 21, 2010
PubMed
Summary
This summary is machine-generated.

CD47 protein, also known as integrin-associated protein (IAP), inhibits macrophage phagocytosis. High CD47 expression on leukemia stem cells (LSCs) in AML patients hinders immune clearance, impacting prognosis and targeted therapy.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • CD47, an immunoglobulin-like protein, binds to SIRPα on macrophages, inhibiting phagocytosis.
  • Normal hematopoietic stem cells (HSCs) express CD47 for stability.
  • Leukemia stem cells (LSCs) in AML patients exhibit high CD47 expression, evading immune clearance.

Purpose of the Study:

  • To review the expression and function of CD47 on HSCs and LSCs.
  • To explore the role of CD47 in Acute Myeloid Leukemia (AML) prognosis.
  • To discuss CD47 as a target for AML therapy.

Main Methods:

  • Literature review of studies on CD47 expression and function in AML.
  • Analysis of CD47's role in immune evasion by LSCs.
  • Examination of CD47-targeting strategies in AML treatment.

Main Results:

  • CD47 acts as a 'don't eat me' signal, protecting LSCs from macrophage phagocytosis.
  • High CD47 expression correlates with poor prognosis in AML.
  • Targeting CD47 may restore macrophage-mediated clearance of LSCs.

Conclusions:

  • CD47 is a critical regulator of immune evasion in AML.
  • Modulating CD47 presents a promising therapeutic avenue for AML treatment.
  • Further research into CD47-based therapies is warranted for improved AML outcomes.